What is calcium monohydrogen phosphate used for in supplements?

Calcium monohydrogen phosphate (CaHPO4) is used as a dual-mineral supplement and food additive providing both elemental calcium (~23% by weight) and phosphorus (~18% by weight) in a single compound. It appears in fortified foods, calcium tablets, and dental products where it supports bone mineralization and enamel remineralization by supplying ions for hydroxyapatite synthesis.

How much elemental calcium is in calcium monohydrogen phosphate?

Calcium monohydrogen phosphate contains approximately 23.3% elemental calcium by molecular weight, meaning a 500 mg dose delivers roughly 116 mg of elemental calcium. This is notably lower than calcium carbonate (~40% elemental calcium) but comparable to calcium citrate (~21%), and it also co-delivers approximately 18% elemental phosphorus, distinguishing it from most other calcium forms.

Is calcium monohydrogen phosphate safe to consume daily?

At levels used in food fortification and standard supplements, calcium monohydrogen phosphate is considered safe by the FDA under GRAS status. However, total daily elemental calcium intake should remain below 2,500 mg (or 2,000 mg for adults over 50) to avoid hypercalcemia, and individuals with chronic kidney disease or hyperphosphatemia should consult a physician before use due to the additional phosphate load.

What is the difference between calcium monohydrogen phosphate and brushite?

Brushite is the dihydrate form of calcium monohydrogen phosphate, written as CaHPO4·2H2O, and is the naturally occurring mineral version found in kidney stones and used in bone cement biomaterials. The anhydrous form (CaHPO4) is more commonly used in food fortification and tablet manufacturing due to its greater stability and higher mineral concentration per gram, while brushite's greater solubility makes it preferred in resorbable bone graft scaffolds.

Does calcium monohydrogen phosphate interact with medications?

Yes, like all calcium-containing supplements, calcium monohydrogen phosphate can chelate and reduce the oral bioavailability of several drug classes including fluoroquinolone antibiotics (e.g., ciprofloxacin), tetracyclines, bisphosphonates (e.g., alendronate), levothyroxine, and iron supplements. A minimum 2-hour separation between calcium supplementation and these medications is clinically recommended to prevent clinically significant reductions in drug absorption.

How does calcium monohydrogen phosphate absorption compare to other calcium supplement forms?

Calcium monohydrogen phosphate provides both calcium and phosphorus in a single compound, which may support balanced mineral absorption compared to calcium-only supplements. However, bioavailability depends on stomach acid levels and individual digestive factors; it is generally recognized as a soluble form suitable for supplementation. The presence of phosphorus may enhance calcium retention in some individuals, though research directly comparing absorption rates to other calcium salts is limited.

Is calcium monohydrogen phosphate suitable for people with kidney disease or phosphate restrictions?

Individuals with chronic kidney disease or those requiring phosphate restriction should consult their healthcare provider before using calcium monohydrogen phosphate, as it provides supplemental phosphorus in addition to calcium. Those with hyperphosphatemia or renal impairment may need to avoid this form and select alternatives like calcium citrate or calcium carbonate instead. Medical supervision is essential when selecting calcium supplements for kidney disease management.

What is the solubility and stability of calcium monohydrogen phosphate in different pH environments?

Calcium monohydrogen phosphate exhibits pH-dependent solubility, being more soluble in acidic environments of the stomach and less soluble at neutral pH. This characteristic makes it bioavailable for absorption in the upper gastrointestinal tract when taken with food or on an empty stomach. Its stability in supplement formulations depends on moisture content and storage conditions, as the monohydrate form may lose water over time if exposed to humidity.

Calcium Monohydrogen Phosphate

Calcium monohydrogen phosphate (CaHPO4) is an inorganic salt that simultaneously delivers calcium and phosphorus, two minerals essential for hydroxyapatite synthesis in bone and teeth. It dissociates in aqueous environments to release Ca2+ and HPO4²⁻ ions, which participate directly in skeletal mineralization and cellular energy metabolism via ATP production.

Category: Mineral Evidence: 2/10 Tier: Emerging

Calcium Monohydrogen Phosphate — Hermetica Encyclopedia

Origin & History

Calcium monohydrogen phosphate (CaHPO₄·nH₂O), also known as dicalcium phosphate, is an inorganic calcium phosphate salt produced synthetically by reacting calcium hydroxide with phosphoric acid. It has no biological origin and is manufactured for industrial uses such as food additives, fertilizers, and pharmaceuticals, existing as a white powder with low water solubility.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for calcium monohydrogen phosphate in any traditional medicine systems. It is a modern synthetic compound primarily developed for industrial applications including fertilizers and leavening agents.

Health Benefits

• Provides supplemental calcium and phosphorus as a food additive (no clinical evidence quality available)
• Used in biomaterials for bone grafts and dental products (materials science applications only, no clinical outcomes)
• Serves as a nutritional source in food fortification (regulatory approval as food additive, no efficacy trials)
• May support mineral supplementation needs (theoretical based on chemical composition, no clinical data)
• Potential application in bone mineralization support (based on structural similarity to bone mineral, no human studies)

How It Works

Upon ingestion, calcium monohydrogen phosphate dissociates into free calcium ions (Ca2+) and hydrogen phosphate ions (HPO4²⁻), which are absorbed in the small intestine via transcellular transport mediated by the TRPV6 calcium channel and paracellular pathways regulated by 1,25-dihydroxyvitamin D3. Phosphate ions are absorbed through sodium-phosphate cotransporters (NaPi-IIb) in intestinal epithelial cells and are subsequently incorporated into hydroxyapatite [Ca10(PO4)6(OH)2], the primary mineral matrix of bone and enamel. Calcium ions also serve as second messengers activating calmodulin-dependent kinases, while phosphate is essential for ATP synthesis, nucleic acid structure, and phospholipid membrane integrity.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specifically on calcium monohydrogen phosphate were found in the research. The compound is primarily studied in materials science for biomedical applications like bone grafts or dental products, but no clinical outcome data or PMIDs are available.

Clinical Summary

Direct clinical trials specifically evaluating calcium monohydrogen phosphate as an isolated oral supplement are largely absent from the literature; most evidence is extrapolated from broader calcium and phosphate supplementation research. A Cochrane review of calcium supplementation trials (n > 50,000 participants) demonstrated modest fracture risk reduction (~12%) with calcium intake, though source-specific data for CaHPO4 were not isolated. In biomaterials research, brushite (the dihydrate form, CaHPO4·2H2O) has been studied in bone graft scaffolds showing osteoconductive properties in small animal models and limited human case series, but randomized controlled trials with clinical endpoints are lacking. Current evidence supporting its use is primarily mechanistic, regulatory (GRAS status by FDA), and extrapolated from mineral physiology rather than compound-specific clinical outcomes.

Nutritional Profile

Calcium Monohydrogen Phosphate (CaHPO4, also known as Dicalcium Phosphate or DCP) is a purely inorganic mineral salt with no macronutrient content (0g protein, 0g fat, 0g carbohydrate, 0g fiber per serving). Micronutrient composition per 1g: Calcium approximately 230-293mg (anhydrous form CaHPO4 yields ~29.5% elemental calcium by molecular weight; dihydrate form CaHPO4·2H2O yields ~23.2% elemental calcium), Phosphorus approximately 180-220mg (~22.8% elemental phosphorus by molecular weight). No vitamins, amino acids, fatty acids, or organic bioactive compounds are present. Bioavailability notes: Calcium from CaHPO4 has moderate bioavailability estimated at 25-35% absorption under normal gastric conditions; absorption is enhanced in acidic gastric pH and reduced in achlorhydria or when taken with high-phytate foods. Phosphorus bioavailability is relatively high at approximately 55-70% as inorganic phosphate is more readily absorbed than organically bound phosphorus. The calcium-to-phosphorus molar ratio is approximately 1:1, which is nutritionally relevant as dietary calcium-to-phosphorus ratios below 1:1 may negatively affect bone metabolism. Contains no sodium, potassium, magnesium, or trace minerals in meaningful quantities. No caloric value. Used in doses typically ranging from 500mg to 1500mg per day in food fortification and supplement contexts.

Preparation & Dosage

No clinically studied dosage ranges are available for calcium monohydrogen phosphate. It is used as a food additive and supplement source of calcium and phosphorus, but specific therapeutic dosing from human studies is absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Magnesium, Vitamin K2, Zinc, Boron

Safety & Interactions

Calcium monohydrogen phosphate is generally recognized as safe (GRAS) by the FDA as a food additive at standard dietary fortification levels, with adverse effects primarily occurring at excessive calcium or phosphorus intakes rather than at typical supplement doses. High phosphate intake can suppress parathyroid hormone secretion and, in individuals with chronic kidney disease (CKD), may worsen hyperphosphatemia, vascular calcification, and renal osteodystrophy, making it contraindicated in advanced CKD without medical supervision. Calcium supplementation in general can reduce absorption of quinolone and tetracycline antibiotics, bisphosphonates, levothyroxine, and iron supplements when taken simultaneously, so a 2-hour separation is advised. Pregnancy safety at dietary fortification levels is considered acceptable, but supplemental doses exceeding the tolerable upper intake level of 2,500 mg elemental calcium per day (2,000 mg for adults over 50) should be avoided due to risk of hypercalcemia and potential fetal harm.